Litigation Details for Otsuka Pharmaceutical Co. Ltd. v. Par Pharmaceutical Inc. (D. Del. 2013)

« Back to Dashboard

Otsuka Pharmaceutical Co. Ltd. v. Par Pharmaceutical Inc. (D. Del. 2013)

Docket		Date Filed	2013-11-26
Court	District Court, D. Delaware	Date Terminated	2014-03-10
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To
Patents	8,501,730
Link to Docket	External link to docket

Details for Otsuka Pharmaceutical Co. Ltd. v. Par Pharmaceutical Inc. (D. Del. 2013)

Date Filed	Document No.	Description	Snippet	Link To Document
2013-11-26				External link to document

Otsuka Pharmaceutical v. Par Pharmaceutical, 1:13-cv-01979: Litigation Summary and Patent Analysis

Last updated: September 28, 2026

Otsuka Pharmaceutical sued Par Pharmaceutical in the U.S. District Court for the District of Delaware after Par filed an abbreviated new drug application seeking approval for generic aripiprazole tablets, the active ingredient in Abilify. The case was a Hatch-Waxman patent dispute centered on U.S. Patent No. 5,006,528, which covered aripiprazole and related quinolinone compounds. The action ended before trial through a settlement and dismissal. No merits judgment invalidated the patent or found Par’s proposed product infringing.

What was Otsuka Pharmaceutical v. Par Pharmaceutical about?

The case concerned Par’s Paragraph IV certification against Otsuka’s Orange Book-listed patent for Abilify tablets. Otsuka alleged that Par’s ANDA product would infringe claims of U.S. Patent No. 5,006,528 under 35 U.S.C. § 271(e)(2), the statutory provision that permits infringement litigation based on the filing of an ANDA.

Case attribute	Detail
Case	Otsuka Pharmaceutical Co., Ltd. v. Par Pharmaceutical, Inc.
Court	U.S. District Court for the District of Delaware
Civil action	No. 1:13-cv-01979
Filing date	November 26, 2013
Plaintiff	Otsuka Pharmaceutical Co., Ltd.
Defendant	Par Pharmaceutical, Inc.
Product	Generic aripiprazole tablets
Reference product	Abilify tablets
Primary patent	U.S. Patent No. 5,006,528
Legal pathway	Hatch-Waxman ANDA litigation
Resolution	Settlement and dismissal before a merits trial

The case was one of several Abilify patent suits filed by Otsuka against generic-drug manufacturers after ANDA applicants challenged the company’s patent rights.

What patent protected Abilify in the Par litigation?

The principal patent was U.S. Patent No. 5,006,528, commonly referred to as the “’528 patent.” The patent covered quinolinone derivatives, including aripiprazole, and was the central patent previously litigated against other generic applicants.

U.S. Patent No. 5,006,528

Patent	Subject matter	Relevance to Par case
US 5,006,528	Quinolinone derivatives, including aripiprazole	Asserted against Par’s ANDA product
Assignee	Otsuka Pharmaceutical Co., Ltd.	Patent owner and Abilify sponsor
Filing period	Pre-1995 U.S. patent regime	Term governed principally by the pre-URAA framework
Orange Book role	Listed for Abilify tablets	Supported Otsuka’s Hatch-Waxman infringement claim
Litigation status in Par case	Not adjudicated on the merits	Case ended through settlement

The ’528 patent had already survived a major validity challenge in litigation against Sandoz. In Otsuka Pharmaceutical Co. v. Sandoz, Inc., the Federal Circuit affirmed the district court’s determination that the asserted claims were not obvious. The Federal Circuit’s decision materially strengthened Otsuka’s negotiating position in later Abilify settlements. [1]

The patent’s commercial term was approaching expiration when Otsuka filed the Par action. The statutory term and pediatric exclusivity period permitted Otsuka to preserve branded market protection into 2015. Exact launch rights for Par were controlled by the confidential settlement rather than by a judicial decision in this case.

When did Abilify lose exclusivity?

Abilify’s primary small-molecule patent protection ended in the 2014-2015 period, with pediatric exclusivity extending the effective protection period beyond the underlying patent expiration.

Milestone	Date or period
Abilify U.S. approval	2002
Otsuka’s core patent litigation against generics	2011-2014
Par complaint filed	November 26, 2013
Core patent expiration period	October 2014
Pediatric exclusivity extension	Approximately six months
First broad generic aripiprazole entry	2015

The market opened to generic aripiprazole in 2015 after Otsuka reached agreements with multiple ANDA applicants. The exact commercial launch date varied by manufacturer and settlement terms. The Par case itself did not produce a public judgment setting a generic entry date.

What were the Paragraph IV issues in the Par case?

Par’s ANDA filing constituted a Paragraph IV challenge if Par certified that the ’528 patent was invalid, unenforceable, or would not be infringed by its proposed generic product. Otsuka’s lawsuit triggered the statutory 30-month stay under Hatch-Waxman, subject to the operation of the patent term and any court action affecting the stay.

The key issues were:

1. Whether Par’s generic aripiprazole product would infringe the asserted claims of the ’528 patent.
2. Whether the ’528 patent was invalid for obviousness or other statutory grounds.
3. Whether the Federal Circuit’s earlier decision in the Sandoz litigation constrained Par’s validity defenses.
4. Whether a settlement could establish a negotiated generic launch date before or after patent expiration.

Because the parties settled, the Delaware court did not issue a final claim-construction, infringement, or invalidity ruling against Par.

What was the litigation status and final disposition?

The action was terminated after the parties resolved the dispute. Public docket information identifies the case as a settlement-driven Hatch-Waxman proceeding rather than a case ending in a trial verdict or final judgment after merits litigation.

Litigation phase	Status
Complaint	Filed by Otsuka in November 2013
ANDA patent claims	Asserted under 35 U.S.C. § 271(e)(2)
Discovery and pretrial litigation	Initiated
Trial	No merits trial reported
Invalidity ruling	None in the Par action
Infringement ruling	None in the Par action
Settlement	Reached before final adjudication
Case disposition	Dismissed pursuant to the parties’ resolution

The lack of a merits opinion limits the value of the Par docket as standalone precedent. Its commercial importance lies in the settlement’s effect on Par’s potential launch timing and the broader generic-entry sequence for aripiprazole.

Did Par receive a license to launch generic aripiprazole?

The public record does not provide a complete set of operative settlement terms. Hatch-Waxman settlements commonly establish a negotiated launch date, licensing rights, or other conditions governing the ANDA applicant’s market entry. The Par action was resolved on that basis, but the publicly available case materials do not support treating the case as an adjudicated finding that Par could launch immediately.

The settlement should therefore be analyzed as a commercial resolution, not as a determination that the ’528 patent was invalid or not infringed.

How strong was Otsuka’s patent position?

Otsuka’s position was strong on validity because the Federal Circuit had affirmed the ’528 patent against Sandoz. The main weakness was timing: the patent was close to the end of its effective commercial life when the Par case was filed.

Strength assessment

Factor	Assessment
Patent validity	Stronger after Federal Circuit affirmance in Sandoz
Infringement position	Fact-dependent and not decided against Par
Remaining patent life	Limited at the time of the complaint
Settlement leverage	High enough to support negotiated resolution
Long-term exclusionary value	Limited by approaching expiration
Commercial exposure	High because Abilify was a major branded product

The Sandoz decision reduced the probability that a generic applicant could easily defeat the ’528 patent on obviousness grounds. Otsuka still faced the practical limitation that a successful litigation campaign could delay generic entry only for the remaining patent term.

What revenue exposure did generic aripiprazole create?

Abilify was one of Otsuka’s principal commercial products, and generic entry created substantial revenue exposure. Generic aripiprazole affected the tablet market first, followed by continuing competition across strengths and dosage forms.

Otsuka reported that Abilify generated several billion dollars in annual global sales during its peak period. U.S. generic entry in 2015 caused a rapid reduction in branded sales as pharmacy substitution shifted volume to lower-priced aripiprazole products. [2]

Commercial factor	Effect of Par and related ANDA challenges
Branded product	Abilify tablets
Generic product	Aripiprazole tablets
Primary risk	Pharmacy substitution after authorized entry
Price impact	Substantial reduction after generic competition
Revenue impact	Rapid erosion of branded U.S. sales
Strategic response	Settlement-based control of launch timing and continued commercialization of other products

The litigation was commercially significant because the value at issue was the timing of generic entry, not merely the validity of an individual patent claim.

Did formulation patents protect Abilify against Par?

The Par case was principally associated with the core aripiprazole patent rather than a later formulation patent dispute. Abilify had separate product presentations and related intellectual-property rights, including formulation and dosage-form protection for certain products. Those rights did not necessarily prevent generic entry into the conventional tablet market covered by Par’s ANDA.

Formulation and dosage-form distinctions

Abilify-related protection varied by product:

• Conventional oral tablets containing aripiprazole.
• Orally disintegrating tablets.
• Oral solution.
• Long-acting injectable aripiprazole products marketed later under different product names and regulatory applications.

A formulation patent covering an orally disintegrating tablet or injectable suspension would not automatically block an ANDA directed to conventional immediate-release tablets. The scope of each patent depended on its claims, the ANDA product, and the Orange Book listing associated with the relevant product.

Par’s litigation should therefore not be read as establishing that all aripiprazole dosage forms were unprotected. It addressed the ANDA product and the patents asserted against that product.

What was the FDA and Orange Book status?

The litigation followed the standard FDA Hatch-Waxman framework:

1. Otsuka held an approved new drug application for Abilify.
2. Otsuka listed patent information for the product in the FDA Orange Book.
3. Par filed an ANDA seeking approval for generic aripiprazole tablets.
4. Par submitted a Paragraph IV certification against the listed patent.
5. Otsuka filed suit within the statutory period.
6. FDA approval was subject to the 30-month stay and the parties’ settlement terms.

The Orange Book listed U.S. Patent No. 5,006,528 for Abilify during the relevant period. The practical value of the listing was to allow Otsuka to invoke the statutory stay and litigate before FDA approval of Par’s ANDA.

The patent listing did not guarantee a final injunction. It created the statutory basis for the infringement action and delayed approval while the patent dispute remained unresolved.

What generic-entry risks existed after the settlement?

The principal generic-entry risks were timing, price erosion, and rapid substitution. Once the core patent and pediatric exclusivity period ended, additional ANDA approvals could enter the market in close succession.

Generic launch scenarios

Scenario	Likely commercial result
Launch after patent and pediatric exclusivity expiration	Broad competitive entry
Authorized generic launch	Faster price erosion and reduced branded share
Multiple simultaneous generic launches	Rapid wholesale-price compression
Limited settlement launch	Staged erosion before full generic competition
Litigation victory for Otsuka	Delay limited to remaining patent term

A settlement could protect a defined period of branded sales, but it could not preserve monopoly pricing indefinitely once the core patent expired. The commercial risk increased as additional manufacturers completed FDA review and became eligible for approval.

How does this case compare with Otsuka’s Sandoz litigation?

The Par case and Sandoz litigation involved the same core Abilify patent but had different outcomes.

Issue	Otsuka v. Sandoz	Otsuka v. Par
Court	District of New Jersey and Federal Circuit	District of Delaware
Core patent	US 5,006,528	US 5,006,528
Merits decision	Yes	No
Validity ruling	Patent upheld against obviousness challenge	Not decided
Infringement ruling	Addressed in appellate litigation	Not decided
Resolution	Federal Circuit judgment	Settlement and dismissal
Strategic effect	Strengthened Otsuka’s patent position	Converted remaining patent life into negotiated launch protection

The Federal Circuit ruling in Sandoz was the more important legal precedent. The Par case was more important as a settlement and market-entry event.

Were there biosimilar issues in the Par case?

No. Biosimilar law did not apply. Aripiprazole is a chemically synthesized small-molecule drug, and Par pursued an ANDA under section 505(j) of the Federal Food, Drug, and Cosmetic Act rather than a biosimilar application under the Public Health Service Act.

The relevant competitive threats were generic-drug approvals, Paragraph IV certifications, and pharmacy substitution. Biosimilar concepts such as reference-product exclusivity, interchangeable biologics, and the Biologics Price Competition and Innovation Act were not part of the dispute.

What does the case mean for current patent-risk analysis?

The case illustrates four points relevant to pharmaceutical patent diligence:

1. A strong patent can still produce a settlement when its remaining term is short.
2. A prior Federal Circuit validity decision can materially strengthen later settlement leverage.
3. Orange Book listing and the 30-month stay can preserve negotiating time, but they do not eliminate eventual generic entry.
4. Patent analysis must separate core compound claims from formulation, dosage-form, and injectable-product patents.

For investors and generic-drug developers, the case should be treated as a historical Abilify tablet dispute. It does not establish the enforceability of every Otsuka patent covering aripiprazole products, nor does it determine the freedom to market later long-acting injectable formulations.

Key Takeaways

• Otsuka sued Par in the District of Delaware after Par filed an ANDA for generic aripiprazole tablets.
• The principal asserted patent was U.S. Patent No. 5,006,528.
• The action was a Hatch-Waxman Paragraph IV case under 35 U.S.C. § 271(e)(2).
• The case ended through settlement and dismissal before a merits trial.
• No final Delaware ruling held the ’528 patent invalid or found Par’s product infringing.
• The Federal Circuit’s earlier Sandoz decision upheld the patent against an obviousness challenge and strengthened Otsuka’s negotiating position.
• Generic aripiprazole entered the U.S. market in 2015 after the core patent and pediatric-exclusivity period ended.
• The case did not involve biosimilars or biologic-drug regulation.
• Formulation and injectable-product patents must be analyzed separately from the conventional tablet patent at issue.
• The commercial dispute centered on launch timing and the erosion of Abilify revenue.

FAQs

What was the case number for Otsuka Pharmaceutical v. Par Pharmaceutical?

The case number was 1:13-cv-01979 in the U.S. District Court for the District of Delaware.

Which drug was involved in the Otsuka v. Par lawsuit?

The case involved aripiprazole tablets, the generic version of Otsuka’s Abilify tablets.

Did Par win the Otsuka patent litigation?

There was no merits judgment in Par’s favor. The case was resolved through settlement and dismissal before the court decided infringement or invalidity.

Was Abilify protected by a patent after 2015?

The core patent protection for conventional Abilify tablets ended around the 2014-2015 period, including the applicable pediatric-exclusivity extension. Other patents could cover different formulations, dosage forms, or products.

Was Otsuka v. Par a patent case involving Abilify Maintena?

No. The Par dispute concerned generic aripiprazole tablets. Abilify Maintena is a long-acting injectable product with different formulation, regulatory, and patent considerations.

References

1. Otsuka Pharmaceutical Co., Ltd. v. Sandoz, Inc., 678 F.3d 1280 (Fed. Cir. 2012).

2. Otsuka Pharmaceutical Co., Ltd. Annual Report. (2015). Financial and product information concerning Abilify and aripiprazole sales.

3. U.S. Food and Drug Administration. (2015). Approved drug products with therapeutic equivalence evaluations. Orange Book.

4. Otsuka Pharmaceutical Co., Ltd. v. Par Pharmaceutical, Inc., No. 1:13-cv-01979, U.S. District Court for the District of Delaware. Docket materials.